RDHL News and Press, Redhill Biopharma Ltd. From 12/07/22

NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL). About RedHill Biopharma Ltd. RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused o...

RedHill Biopharma Closes $8.0 Million Underwritten Public Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Dec. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company,...

RedHill Biopharma Prices $8.0 Million Underwritten Public Offering PR Newswire TEL AVIV, Israel , and RALEIGH, N.C. , Dec. 2, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical compan...

RedHill Biopharma Announces Proposed Public Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced t...

RedHill Biopharma Announces Q3/22 Results and Operational Highlights PR Newswire Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6 million ; Operating...

RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury PR Newswire Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective impact on hematologi...

RedHill Biopharma ( NASDAQ: RDHL ) stock rose ~9% on Monday after the company said it reached a non-binding agreement with HCR Collateral Management to settle all debt obligations in exchange for rights to constipation drug Movantik (naloxegol). The potential ...

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published Canada NewsWire Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supp...

RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik® PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("...

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates PR Newswire Financial update : Q2/22: Net revenues of $18.3 million ; Operating loss of $9.2 million ; Cash balance [1] of $43.2 million as of June 30, 2022 ; Restated Q1/22...